ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial
News Dec 26, 2008
ImmunoCellular Therapeutics, Ltd. has presented preliminary, promising clinical data from a Phase I trial, evaluating ICT-107, the company’s dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma.
ICT-107 was well tolerated, and no significant adverse events were reported. These data were reported at the Society for Neuro-Oncology 13th Annual Scientific Meeting in Las Vegas, Nevada.
The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant type of brain cancer. The trial enrolled 19 patients and was conducted at Cedars-Sinai Medical Center.
Of the 19 patients enrolled, seventeen patients are still alive, with eight patients surviving at least one year after the surgery that preceded their vaccine treatment. Ten patients were evaluated for immune responses, and five of them had a significant immune response to at least one tumor-associated antigen. Patients demonstrating an immune response are exhibiting a trend toward longer overall survival. IMUC expects to present additional follow-up data on this trial at a medical meeting in 2009.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019